Forward of IPO, Suraksha Diagnostic collects Rs 254 crore from anchor buyers – Occasions of India
NEW DELHI: Built-in diagnostic chain Suraksha Diagnostic Ltd on Thursday stated it has mobilised Rs 254 crore from anchor buyers, a day earlier than opening of its preliminary share-sale for public subscription. The highest anchor buyers within the IPO included Nippon India Mutual Fund, Kotak MF, Aditya Birla Solar Life MF, Quant MF and Carnelian Bharat Amritkaal Fund, in accordance with a round uploaded on BSE’s web site.
The corporate has allotted 57.57 lakh fairness shares to 16 funds at Rs 441 apiece, which can also be the higher finish of the value band. This aggregates the transaction dimension to Rs 254 crore, the round confirmed.
The Rs 846-crore preliminary share-sale will open for public subscription on November 29 and conclude on December 3. The shares will probably be out there within the value vary of Rs 420 to Rs 441 apiece.
The Kolkata-headquartered firm’s IPO consists of an Provide for Sale (OFS) of 19,189,330 fairness shares price Rs 846.25 crore, on the higher finish of the value band, by promoters and investor shareholders, with no recent difficulty element.
Beneath the OFS, promoters Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma; and buyers OrbiMed Asia II Mauritius Ltd, Munna Lal Kejriwal and Santosh Kumar Kejriwal will offload shares.
Because the difficulty is totally an OFS, the corporate is not going to obtain any proceeds and all of the funds will go to the promoting shareholders.
Explaining the rationale for going public, the corporate stated it’s aimed toward attaining the good thing about itemizing fairness shares on the inventory exchanges and finishing up OFS for the promoting shareholders.
On the higher finish of the value band, the corporate’s market capitalisation stands at round Rs 2,300 crore.
Suraksha Diagnostic provides a one-stop built-in answer for pathology and radiology testing and medical session providers to its prospects by way of its intensive operational community, consisting of a flagship central reference laboratory, 8 satellite tv for pc laboratories and 194 buyer touchpoints which embody 48 diagnostic centres, and 146 pattern assortment centres (primarily franchised), throughout West Bengal, Bihar, Assam and Meghalaya as of March 31, 2024.
Throughout fiscal 2024, it carried out about 5.98 million checks serving roughly 1.14 million sufferers.
Half of the problem dimension has been reserved for certified institutional consumers (QIBs), 35 per cent for retail buyers and the remaining 10 per cent for non-institutional buyers.
ICICI Securities Ltd, Nuvama Wealth Administration Ltd and SBI Capital Markets Ltd are the book-running lead managers to the problem. The fairness shares are anticipated to be listed on BSE and NSE on December 6.
